Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity

被引:167
作者
Volpert, OV
Dameron, KM
Bouck, N
机构
[1] NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA
[2] NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA
关键词
neovascularization; fibrosarcoma; VEGF; thrombospondin; tumor progression;
D O I
10.1038/sj.onc.1200977
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
As normal cells progress to malignancy they must acquire an angiogenic phenotype that will enable them to attract the blood vessels necessary to support their progressive growth. Here we define the mechanism by which human fibroblasts cultured from Li Fraumeni patients and progressing to tumorigenicity in vitro become angiogenic. Initially cells were anti-angiogenic due to the secretion of high levels of inhibitory thrombospondin that overrode the modest amounts of the major inducer, vascular endothelial cell growth factor (VEGF), that were also produced. Cells became fully angiogenic in two steps, the first dependent on the loss of both alleles of wild-type p53 which caused a drop of at least 20-fold in secreted thrombospondin and a fourfold increase in secreted VEGF. Angiogenic activity increased again upon transformation by activated ras due to a further twofold increase in VEGF. Changes in relative levels of VEGF mRNA were sufficient to account for changes in secreted protein levels and in overall angiogenic activity. These studies demonstrate that an angiogenic phenotype able to support tumorigenicity can arise in a step-wise fashion in response to both oncogene activation and tumor suppressor gene loss and involve both a decrease in the secretion of inhibitors and the sequential ratcheting up of the secretion of inducers of angiogenesis.
引用
收藏
页码:1495 / 1502
页数:8
相关论文
共 32 条
[1]   BOTH N-RAS AND C-MYC ARE ACTIVATED IN THE SHAC HUMAN STOMACH FIBRO-SARCOMA CELL-LINE [J].
ANDEOL, Y ;
NARDEUX, PC ;
DAYAGROSJEAN, L ;
BRISON, O ;
CEBRIAN, J ;
SUAREZ, H .
INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (05) :732-737
[2]  
ANDREASSEN A, 1993, CANCER RES, V53, P468
[3]  
[Anonymous], 1995, The molecular basis of cancer
[4]  
BISCHOFF FZ, 1990, CANCER RES, V50, P7979
[5]  
BISCHOFF FZ, 1991, ONCOGENE, V6, P138
[6]   How tumors become angiogenic [J].
Bouck, N ;
Stellmach, V ;
Hsu, SC .
ADVANCES IN CANCER RESEARCH, VOL 69, 1996, 69 :135-174
[7]  
CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3
[8]  
CORDONCARDO C, 1994, CANCER RES, V54, P794
[9]   CONTROL OF ANGIOGENESIS IN FIBROBLASTS BY P53 REGULATION OF THROMBOSPONDIN-1 [J].
DAMERON, KM ;
VOLPERT, OV ;
TAINSKY, MA ;
BOUCK, N .
SCIENCE, 1994, 265 (5178) :1582-1584
[10]   THE P53 TUMOR-SUPPRESSOR GENE INHIBITS ANGIOGENESIS BY STIMULATING THE PRODUCTION OF THROMBOSPONDIN [J].
DAMERON, KM ;
VOLPERT, OV ;
TAINSKY, MA ;
BOUCK, N .
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1994, 59 :483-489